Regeneron Reports Results of Eylea (aflibercept) in P-III PANORAMA Study for Patients with Diabetic Retinopathy
Shots:
- The P-III PANORAMA study involves assessing Eylea [inj. 2mg (0.05ml)- q8w/q16w] vs sham in 402 patients with moderately severe to severe NPDR without DME
- The P-III PANORAMA study results: @2yrs. 75% reduction in vision-threatening events- patients demonstrated greater improvement in the DRSS score from baseline (80% @52wks and 50% @100 wks.) in q8w group while >2-step DRSS scores remained consistent (65% @52 wks. vs 62% @100 wks.) in q16w group
- Eylea is a VEGF inhibitor targeting VEGF-A and PLGF- formulated as an injection for the eye- act by blocking the growth of new blood vessels and by decreasing vascular permeability in the eye and is approved therapy for Wet AMD- macular edema following RVO- DME and DR in the US
Click here to read full press release/ article | Ref: Regeneron | Image: StraitTimes
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com